The Developmental Core (Core B) will support and develop the next-generation of HIV/AIDS researchers at the UR. The Core will administer the CFAR's pilot grant program, conduct mentoring and career development of young investigators, and provide seminars and scientific symposia that create an outstanding scientific and intellectual environment for HIV/AIDS research at the UR. The Core will use its pilot program to support young faculty and to also promote overall CFAR objectives, including the establishment of new multidisciplinary collaborations and the promotion of innovative studies that support the mission of the CFAR's Scientific Working Groups (SWGs) and leverage unique institutional assets. During our funding cycle as a Developmental CFAR (D-CFAR), this Core has funded 26 pilot awards in an aggregate amount of $641,606, which have yielded a 10:1 return on investment in terms of new grant awards. Its pilot and mentoring programs have also had a profound impact on the career development of young HIV/AIDS researchers. This has included 2 KL2 awards from the UR CTSI;2 awards from the national Creative New Ideas in HIV Research (CNIHR) program (out of only 22 total awards made between 2010 and 2012);4 CFAR supplement awards in 2011 (including 1 of only 2 nanotech supplements awarded nationally);and the academic promotion of 6 young faculty members.
Three Aims are proposed.
Aim 1 will stimulate new research on HIV/AIDS by funding pilot awards targeted to: young faculty members;innovative studies with potential for high impact;and multidisciplinary collaborations that span different departments and schools, including projects that leverage unique institutional assets.
Aim 2 will provide comprehensive, structured mentoring support for the early career development of young faculty, and a grant pre-review service intended to enhance the quality of extramural grant applications from new investigators. Finally, Aim 3 will create an outstanding intellectual and scientific environment for HIV/AIDS researchers, by supporting seminars, symposia, and a range of training courses and workshops.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-UKS-A (J1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Rochester
United States
Zip Code
McMillan, JoEllyn; Szlachetka, Adam; Zhou, Tian et al. (2018) Pharmacokinetic testing of a first generation cabotegravir prodrug in rhesus macaques. AIDS :
Hammond, Jennetta W; Qiu, Wen Q; Marker, Daniel F et al. (2018) HIV Tat causes synapse loss in a mouse model of HIV-associated neurocognitive disorder that is independent of the classical complement cascade component C1q. Glia 66:2563-2574
Dompreh, Albert; Tang, Xiaoli; Zhou, Jianlin et al. (2018) Effect of Genetic Variation of NAT2 on Isoniazid and SLCO1B1 and CES2 on Rifampin Pharmacokinetics in Ghanaian Children with Tuberculosis. Antimicrob Agents Chemother 62:
Leblanc, Natalie M; Mitchell, Jason (2018) Providers' Perceptions of Couples' HIV Testing and Counseling (CHTC): Perspectives From a U.S. HIV Epicenter. Couple Family Psychol 7:22-33
Rice, John D; Johnson, Brent A; Strawderman, Robert L (2018) Modeling the rate of HIV testing from repeated binary data amidst potential never-testers. Biostatistics :
Nunn, Amy; Parker, Sharon; McCoy, Katryna et al. (2018) African American Clergy Perspectives About the HIV Care Continuum: Results From a Qualitative Study in Jackson, Mississippi. Ethn Dis 28:85-92
Sillman, Brady; Bade, Aditya N; Dash, Prasanta K et al. (2018) Creation of a long-acting nanoformulated dolutegravir. Nat Commun 9:443
Ogunbajo, Adedotun; Kershaw, Trace; Kushwaha, Sameer et al. (2018) Barriers, Motivators, and Facilitators to Engagement in HIV Care Among HIV-Infected Ghanaian Men Who have Sex with Men (MSM). AIDS Behav 22:829-839
Piekna-Przybylska, Dorota; Maggirwar, Sanjay B (2018) CD4+ memory T cells infected with latent HIV-1 are susceptible to drugs targeting telomeres. Cell Cycle 17:2187-2203
Ocque, Andrew J; Hagler, Colleen E; Morse, Gene D et al. (2018) Development and validation of an LC-MS/MS assay for tenofovir and tenofovir alafenamide in human plasma and cerebrospinal fluid. J Pharm Biomed Anal 156:163-169

Showing the most recent 10 out of 192 publications